All research in Biopharmaceuticals & Rare Diseases — 1 reports.
argenx is the global leader in antibody therapies for rare autoimmune disease and the first-in-class pioneer of the FcRn-inhibitor field. Its core product Vyvgart (efgartigimod) is now approved across three indications (gMG, CIDP globally plus ITP in Japan), with roughly 19,000 patients on therapy, FY2025 net sales of USD 4.15 billion (+90%), and a first-ever positive operating profit of USD 1.05 billion. Vision 2030 targets 50,000 patients, 10 labels, and 5 Phase III molecules. Rating Watch: a genuinely strong asset whose USD 882.41 price already prices in smooth execution, so the entry window opens only on a pullback to USD 720 or below.
